Counting mitoses: SI(ze) matters!

Ian A. Cree1 · Puay Hoon Tan2 · William D. Travis3 · Pieter Wesseling4,5 · Yukako Yagi3 · Valerie A. White1 · Dilani Lokuhetty1,6 · Richard A. Scolyer7

Received: 16 February 2021 / Revised: 16 April 2021 / Accepted: 20 April 2021 / Published online: 2 June 2021
© World Health Organization 2021. This article is published with open access

Abstract
Mitoses are often assessed by pathologists to assist the diagnosis of cancer, and to grade malignancy, informing prognosis. Historically, this has been done by expressing the number of mitoses per high power fields (HPFs), ignoring the fact that microscope fields may differ substantially, even at the same high power (×400) magnification. Despite a requirement to define HPF size in scientific papers, many authors fail to address this issue adequately. The problem is compounded by the switch to digital pathology systems, where ×400 equivalent fields are rectangular and also vary in the area displayed. The potential for error is considerable, and at times this may affect patient care. This is easily solved by the use of standardized international (SI) units. We, therefore, recommend that features such as mitoses are always counted per mm2, with an indication of the area to be counted and the method used (usually “hotspot” or “average”) to obtain the results.

Background
Mitoses and other features, such as the degree of nuclear atypia, necrosis, vascularity, and invasion are evaluated by pathologists in making a diagnosis of cancer, and to grade malignancy, informing prognosis. In many publications, mitotic activity is given as a mitotic count, expressed as the number of mitoses per high-power field (HPF), or per 10 or 50 HPFs. High power is usually taken as ×400 overall magnification, where a ×40 objective is paired with a ×10 eyepiece. Unfortunately, different combinations of microscopes and lenses result in widely variable actual areas of the high-power field. This may impart significant measurement errors amongst observers using different microscopes. A number of tumor types in which the diagnosis may be affected is shown in Table 1, based on searches of the current fourth and fifth edition WHO classification of tumors.

It is accepted that the best practice is to at least define the size of these fields in scientific publications [1], but unfortunately, journals have not enforced the requirement that the size of the field used for a study be specified. It is our view that the use of HPF should be abandoned completely moving forward and replaced by standardized international (SI) units, which are the required units of work in medicine and science, as the term HPF cannot be standardized. The use of millimeters squared (mm2) gives an appropriately standardized unit for area measurement and mitoses per mm2 are easily calculated (Fig. 1). Furthermore, the data obtained are independent of the microscope and magnification used and the results obtained in different parts of the world would therefore become more comparable.

The extent of the issue
The problems caused by the use of HPF as a unit of area measurement have long been recognized, particularly in
Mitotic activity: definition of terms

The problem is particularly important for the assessment of cell proliferation. Cell division by mitosis is recognizable in histological sections and has long provided an important
table representation of this document as if you were reading it naturally.
means of assessing the proliferation of tumors. There are essentially three options for the measurement of cell proliferation by mitosis:

Mitotic count is a simple density measurement, now usually expressed as the number of mitoses per mm² rather than per HPF. It still takes no account of cell size, the presence of intratumoral stroma separating tumor cells which impacts tumor cell density, the number of cells present in the defined area, inter-observer variation in the assessment of what is recognized by an individual pathologist as a mitotic figure, or the thickness of the section. These issues have surfaced recently as artificial intelligence (AI) tools begin to be used to count mitoses in digital whole slide images [16–18].

The mitotic index is the number of mitoses expressed as a percentage of the number of neoplastic cells present, identification of which can prove to challenge [19]. It does not depend on the area assessed, and so overcomes the issues of the area, intratumoral stroma, and cell size. This is not routinely done by pathologists who do not have time to count hundreds of cells in their routine clinical practice. However, it can be assessed using computational pathology methods on digital images, which may increase its utility in future studies.

The mitotic rate is defined as the rate at which cells are entering the mitotic (M) phase of the cell cycle, expressed as a percentage of the cells counted per hour. Whereas mitotic count and index are dependent on the duration of mitosis (which is variable), the mitotic rate is not affected, but assessment usually requires metaphase arrest or labeling methods in viable cells or tissue. It is therefore limited in its practical application for diagnostic purposes.

Both mitotic count and mitotic index depend on the recognition of mitoses. This can be assisted by immunohistochemistry for proteins expressed during mitosis, such as monoclonal mitotic protein-2 (MPM-2) [20] and phosphohistone H3 (PHH3) [21], though these stains may not correlate directly with morphological counts. While mitotic index and Ki-67 can both be used to measure cell proliferation, it is important to recognize that Ki-67 positively stains nuclei in G1, G2, or S phase, which is usually considerably longer and more variable than the M phase.

Mitotic activity varies within different regions of a tumor, so it is also important to decide whether a “hotspot” or “average” counting method should be employed. The recommended approach with the “hotspot” method is to first assess all slides from the tumor at relatively low power to find the region of the tumor containing more mitoses, so-called hotspots. After counting the mitoses in the initial high-power field with the highest number of mitoses within the “hotspot”, the count is extended to immediately adjacent non-overlapping fields until a specified area has been assessed. If no hotspot can be found and mitoses are sparse and/or randomly scattered throughout the tumor, then a representative mitosis is chosen and, beginning with that field, the count is then extended to immediately adjacent non-overlapping fields until the predetermined area has been assessed. With the “average counting method”, mitoses are assessed in randomly selected HPF and the average number of mitoses in a predefined area is expressed as a number per mm². Modern computational systems have the capacity to do both across the whole slide and give a mean or median (for skewed data) depending on the requirements of the pathologist. However, when dealing with small biopsies, the use of mitotic counts is potentially problematic and prone to greater error due to sampling bias.

Pre-analytical factors can affect mitotic activity, particularly the time to fixation which may be prolonged if fresh tissue is required for other investigations, and ischemia within larger specimens. Some have identified a decline in the number of observable mitotic figures after delayed fixation [22]. However, delayed fixation may result in an increased mitotic count [23] as “the increase in mitotic figures in resection specimen and the significant shift towards metaphase figures is not due to a sampling artifact but reflects ongoing cell cycle activity in the resected tumor tissue due to fixation delay. The dwindling energy supply will eventually arrest tumor cells in metaphase, suggesting that rapidly fixed biopsy material better represents true tumor biology” [24], though cell stress may lead to an arrest in the M-phase [25].

Mitoses are usually detectable in multiple slices through cells, and tissue sections do vary in thickness; it is strictly true that the counting of mitoses per area of section is a volumetric assessment, and the thickness of the section should be considered [3]. However, in routine clinical practice utilizing good quality H&E stained sections of 3–5 μm in thickness, considerably less than the thickness of the cell, this is a relatively minor source of error and by convention is ignored. The recognition of mitoses is to some degree subjective. Nevertheless, the interobserver reproducibility of assessment of mitotic count by pathologists with varying levels of experience has been shown to be excellent in melanoma [4].

Best practice for mitotic counts

There is evidence in melanoma that when mitoses are measured using a defined method and expressed as a number per mm², there is excellent interobserver reproducibility in contrast to other studies in which mitoses have been expressed as number per HPF with poorer interobserver reproducibility [4, 26]. In the breast, a preliminary study proposed leveraging digital slides to count mitoses for phyllodes tumor grading over a larger tumor area of the entire tissue section than just 10 HPF. This could reduce potential interobserver selection
bias, and would necessarily require reporting of mitotic counts per mm² [27]. Strict criteria should be applied for accepting a mitotic figure in distinction from a pyknotic or apoptotic nucleus, and if there is uncertainty about a mitotic figure, it should not be counted.

In the fifth Edition WHO Classification of Tumors, SI units are used [28] and all mitotic counts must be reported per mm², and if necessary qualified by the addition of a minimum area to count and whether an average across the tumor or hotspot counting method is to be used. It is acceptable to add “…count an area of at least ‘n’ mm²… in the area of highest mitotic activity” in brackets. Table 2 is included at the beginning of each WHO Blue Book volume for easy conversion of mitoses/mm² to HPF based on knowing the diameter of the HPF in a pathologist’s own microscope. In some volumes where the use of HPF has commonly been used in the past as a diagnostic criterion, we have also provided the equivalent mitotic count expressed in HPF of defined size in the text to assist pathologists who are unfamiliar with these issues. Slides with 1 mm scales are widely available, making it a simple matter to check the size of HPF directly (Fig. 1) and these can also be scanned to check digital pathology systems.

Unfortunately, if the diameter of the HPF used was not defined in the original research publication on a specific tumor, it is impossible to convert the data to mitoses per mm² [29]. This leaves authors and editors in a difficult position, though a descriptive statement may be utilized. Such older studies often predate changes in treatment, and/or diagnosis, and probably need to be repeated. This is often the best solution, unless treatment has changed with an impact on survival, and can be done relatively simply if the slides and blocks are still available [30].

For a number of tumor types within the WHO Classification of Tumors [7, 8] where the mitotic count is a diagnostic criterion, the area to be assessed has been defined as the number of HPFs which must be assessed for mitoses by a pathologist, rather than the total area to be counted in mm². This is erroneous but relatively unlikely to cause problems when many mitoses are present, though potentially problematic in small biopsies. The area to be counted may, in some instances, be based on published scientific studies that have evaluated the degree of variation in mitotic counts across sections, using cumulative mean or other methods to calculate the area required to get a reproducible measurement, but in other cases, it appears arbitrary.

For the pathologist trying to determine the correct measurement, the problem is compounded by the requirement to assess hotspots (Fig. 2), or even the edge of tumors where there is the likelihood of interaction with the tumor micro-environment, and oxygen levels are likely to be best suited to neoplastic cell growth. This is of course something of Pandora’s box, but recent advances in digital pathology, make it a much less onerous task to return to this problem for those tumors where count per unit area is an important parameter determining malignancy or prognosis. It will be important to compare the methods wherever possible to avoid grade migration [31], though this seems relatively unlikely [16].

### Counting other features

The problem is not restricted to counting mitoses. Pathologists count other features within tumors and again, if these

| Field diameter (mm) | Field area (mm²) | Approximate number of fields per 1 mm² |
|--------------------|-----------------|---------------------------------------|
| 0.40               | 0.126           | 8                                     |
| 0.41               | 0.132           | 8                                     |
| 0.42               | 0.138           | 7                                     |
| 0.43               | 0.145           | 7                                     |
| 0.44               | 0.152           | 7                                     |
| 0.45               | 0.159           | 6                                     |
| 0.46               | 0.166           | 6                                     |
| 0.47               | 0.173           | 6                                     |
| 0.48               | 0.181           | 6                                     |
| 0.49               | 0.188           | 5                                     |
| 0.50               | 0.196           | 5                                     |
| 0.51               | 0.204           | 5                                     |
| 0.52               | 0.212           | 5                                     |
| 0.53               | 0.221           | 5                                     |
| 0.54               | 0.229           | 4                                     |
| 0.55               | 0.237           | 4                                     |
| 0.56               | 0.246           | 4                                     |
| 0.57               | 0.255           | 4                                     |
| 0.58               | 0.264           | 4                                     |
| 0.59               | 0.273           | 4                                     |
| 0.60               | 0.283           | 4                                     |
| 0.61               | 0.292           | 3                                     |
| 0.62               | 0.302           | 3                                     |
| 0.63               | 0.312           | 3                                     |
| 0.64               | 0.322           | 3                                     |
| 0.65               | 0.332           | 3                                     |
| 0.66               | 0.342           | 3                                     |
| 0.67               | 0.352           | 3                                     |
| 0.68               | 0.363           | 3                                     |
| 0.69               | 0.374           | 3                                     |

Adapted from: WHO Classification of Tumors Editorial Board. Breast tumors. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumors series, 5th ed.; vol. 2). https://publications.iarc.fr/581.
are expressed as a number per HPF, an error in their assessment is inevitable. In addition to mitoses, apoptotic bodies can be counted and expressed per mm² [32]. Counting cells of particular types can be informative, and if this is done by morphology on H&E stained sections, then the counts should also be expressed per mm². Follicular lymphoma is a case in point. In the 2017 fourth edition (revised) WHO Classification of Tumors [15], the count of centroblasts per HPF is used in grading. The field size is given as 0.159 mm², but if this is ignored and a modern microscope with a field size of 0.23 mm² used, then 30% more mitoses may be counted and the grade given may be higher than intended. As Table 2 shows, only 7 HPF and not 10, should be counted in this instance.

Microvessel density is a prognostic factor in a number of disparate tumor types, and has often been expressed as "vessels per HPF" with the inevitable consequence that results of studies cannot be compared unless the HPF is defined [1]. The best practice is to express these per mm² as well, and this is compatible with digital systems that provide an automated assessment.

Tumor budding is an increasingly used prognostic factor in colorectal cancer and is assessed according to consensus guidelines [33], with definitions based on per mm².

**Computational pathology**

The issue of mitotic counts on digital images is particularly urgent for those pathology departments which are switching from using traditional light microscopes to digital pathology systems, as the latter does not have a round field of view (although a circular area of interest can usually be defined). There is no way of meeting any current guidance which specifies the use of HPF unless this is defined and thresholds converted accordingly. However, digital pathology systems do have the capacity to measure areas with considerable accuracy, without the requirement for calculation. For those using such systems, automated counting of cells identified by immunohistochemistry, or mitoses identified by deep learning methods, it is already possible to express these values per mm² [16–18, 34]. This makes it even more important to avoid the use of non-standardized units and to switch to mitotic counts per mm².

There is an increasing move to reporting pathology using digital images as the technology has improved significantly over the last 10 years, putting simple image analysis into the hands of pathologists during their routine work. Planimetric methods have been used for many years in research, but simple measurements of tumor depth and distance from margins of excision are now performed on digital images providing more accurate results. More sophisticated computational methods can also be applied to assess mitotic counts and the evidence is that these are as good or better than direct observation using the microscope, and are improving with time [17, 32, 35–37]. Comparative studies remain important to avoid potential grade migration [31]. The ability of pathologists to count mitoses accurately to provide prognostic information to clinicians has the potential to be greatly improved as a result.

In the future, digital pathology efforts may even facilitate the development of mitosis counting algorithms utilizing assessment of the entire tumor (even over multiple slides, levels, or biopsies). Furthermore, AI and machine learning may provide new opportunities to not only more precisely measure or even automate mitotic index measurements on specific tumor types, but they may also enable mitotic index and other digitally assessed tumor characteristics to be incorporated into new ways of classifying tumors.

**Recommendations for future work**

Until digital pathology systems become more widely available throughout the world, there continues to be a need for pathologists to assess cell proliferation by counting mitoses for tumor diagnosis, grading, and prognosis. It is necessary to update knowledge in this area for a large number of different tumor types not only because an undefined HPF was often used in the original studies, but also because changes in treatment may mean that thresholds established long ago for mitotic counts (often as part of
tumor grading) are no longer relevant when assessed with a modern microscope. Given that dichotomization of continuous variables is fraught with danger [38], it is arguably necessary to revisit such data, ideally in large studies or clinical trials, on a regular basis. As many trials now often require centralized pathology review, for which digital images are often obtained, there is some hope that this may be feasible. It is of course necessary for the pathologists involved in such studies and trials to define their measurements, using SI units, to allow corroboration of results across studies.

Implementation of standardized measurement is well advanced in many areas of pathology, but we hope that both scientific journal editors and the authors of pathology texts will insist on the use of mitoses per mm$^2$, rather than per HPF.

Acknowledgements We are grateful to all authors and editors involved in the fifth Edition of the WHO Classification of Tumors. This paper is a product of their work as much as ours in evaluating and debating the research that underpins the diagnosis of tumors. We wish to thank Dr. Ozgur Mete for his careful reading of the final manuscript.

Author contributions This paper is based on discussions over many years. It was written jointly by the authors with input from those listed in the acknowledgments section, and the final draft agreed upon by all involved.

Compliance with ethical standards

Declarations The content of this article represents the personal views of the authors and does not represent the views of the authors’ employers and associated institutions. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

Conflict of interest RAS is supported by a Commonwealth Government of Australia National Health and Medical Research Council of Australia (NHMRC) Practitioner Fellowship.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the World Health Organization, its Board of Directors, or the countries they represent. Open Access This article is licensed under the terms of the Creative Commons Attribution 3.0 IGO License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the World Health Organization, provide a link to the Creative Commons licence and indicate if changes were made. The use of the World Health Organization’s name, and the use of the World Health Organization’s logo, shall be subject to a separate written licence agreement between the World Health Organization and the user and is not authorized as part of this CC-IGO licence. Note that the link provided below includes additional terms and conditions of the licence. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/3.0/igo/.

References

1. Cree IA, Foss AJ, Luthert PJ. Undefined high-power fields. Lancet. 1996;347:273–4.
2. Ellis PS, Whitehead R. Mitosis counting—a need for reappraisal. Hum Pathol. 1981;12:3–4.
3. Sadler DW, Cognill SB. Histopathologists, malignancies, and undefined high-power fields. Lancet. 1989;8641:785–6.
4. Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571–6.
5. McGovern VJ, Cochran AJ, Van der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12–21.
6. Scolyer RA, Thompson JF. Mitotic rate in melanoma should be recorded as the number of mitoses per mm$^2$ (not per high power field); surgeons tell your pathologists! Am J Surg. 2013;206:142–3.
7. WHO Classification of Tumours Editorial Board. WHO classification of tumours: female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
8. WHO Classification of Tumours Editorial Board. WHO classification of tumours: soft tissue and bone tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
9. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44.
10. Parham DM, Hagen N, Brown RA. Simplified method of grading primary carcinomas of the breast. J Clin Pathol. 1992;45:517–20.
11. Laroye GJ, Minkin S. The impact of mitotic index on predicting outcome in breast carcinoma: a comparison of different counting methods in patients with different lymph node status. Mod Pathol. 1991;4:456–60.
12. Jannink I, van Diest PJ, Baak JP. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995;26:1086–92.
13. Garbe C, Eigentler TK, Bauer J, Blöndorn-Schlicht N, Fend F, Hantschke M, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. J Dtsch Dermatol Ges. 2011;9:690–9.
14. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 4th ed. In: Bosman FTJ, Lakhani SR, Jaffe ES, Ohgaki H (eds). Lyon: International Agency for Research on Cancer, 2012.
15. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. In: Bosman FTJ, Lakhani SR, Jaffe ES, Ohgaki H (eds). Lyon: International Agency for Research on Cancer, 2017.
16. Balkenhol MCA, Tellez D, Vreuls W, Claesen PC, Pinckaers H, Ciompi F, et al. Deep learning assisted mitotic counting for breast cancer. Lab Invest. 2019;99:1596–606.

17. Tabata K, Uraoka N, Benhamida J, Hanna MG, Sirintrapun SJ, Gallas BD, et al. Validation of mitotic cell quantification via microscopy and multiple whole-slide scanners. Diagn Pathol. 2019;14:65.

18. Wang M, Aung PP, Prieto VG. Standardized method for defining a 1-mm² region of interest for calculation of mitotic rate on melanoma whole slide images. Arch Pathol Lab Med. 2021. https://doi.org/10.5858/arpa.2020-0137-OA.

19. Saldanha G, Ali R, Bakshi A, Basiouni A, Bishop R, Colloby P, et al. Global and mitosis-specific interobserver variation in mitotic count scoring and implications for malignant melanoma staging. Histopathology. 2020;76:803–13.

20. Hu W, Mitchell MF, Boiko IV, Linares A, Kim HG, Malpica A, et al. Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomark Prev. 1997;6:711–8.

21. Nielsen PS, Riber-Hansen R, Schmidt H, Steiniche T. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma. Diagn Pathol. 2016;11:35.

22. Cross SS, Start RD, Smith JH. Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol. 1990;43:597–9.

23. Graem N, Helweg-Larsen K. Mitotic activity and delay in fixation of tumour tissue. The influence of delay in fixation on mitotic activity of a human osteogenic sarcoma grown in athymic nude mice. Acta Pathol Microbiol Scand A. 1979;87A:375–8.

24. Lehr HA, Rochat C, Schaper C, Nobile A, Shanouda S, Vijgen S, et al. Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. Mod Pathol. 2013;26:336–42.

25. Burgess A, Rasouli M, Rogers S. Stressing mitosis to death. Front Oncol. 2014;4:140.

26. Larsen TE, Little JH, Orell SR, Prade M. International pathologists congruence survey on quantitation of malignant melanoma. Pathology. 1980;12:245–53.

27. Chow ZL, Thike AA, Li HH, Nasir NDM, Yeong JPS, Tan PH. Counting mitoses with digital pathology in breast phyllodes tumors. Arch Pathol Lab Med. 2020;144:1397–400.

28. Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76:151–6.

29. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accott NA, Azzola MF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426–33.

30. Huang W, Nebiolo C, Esbna K, Hu R, Lloyd R. Ki67 index and mitotic count: correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors. Ann Diagn Pathol. 2020;48:151586.

31. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–8.

32. Cree IA, Nurbhai S, Milne G, Beck JS. Cell death in granulomata: the role of apoptosis. J Clin Pathol. 1987;40:1314–9.

33. Studer L, Blank A, Bokhorst JM, et al. Taking tumour budding to the next frontier—a post-ITBCC 2016 review. Histopathology. 2021;78:476–84.

34. Kim D, Pantanowitz L, Schüffler P, Yarlagadda DVK, Ardon O, Reuter VE, et al. (Re) defining the high-power field for digital pathology. J Pathol Inform. 2020;11:33.

35. Malon C, Brachtel E, Cosatto E, Graf HP, Kurata A, Kuroda M, et al. Mitotic figure recognition: agreement among pathologists and computerized detector. Anal Cell Pathol. 2012;35:97–100.

36. Veta M, van Diest PJ, Willems SM, Wang H, Madabhushi A, Cruz-Roa A, et al. Assessment of algorithms for mitosis detection in breast cancer histopathology images. Med Image Anal. 2015;20:237–48.

37. Puri M, Hoover SB, Hewitt SM, Wei BR, Adissu HA, Halsey CHC, et al. Automated computational detection, quantitation, and mapping of mitosis in whole-slide images for clinically actionable surgical pathology decision support. J Pathol Inf. 2019;10:4.

38. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.